Cipla To Shift Focus To High-Margin Drugs In U.S., Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
Cipla plans to change its commercial strategy and focus on high-margin oncology and inhaler products in the U.S. and emerging markets such as Malaysia.